Travis J. Cohoon

Travis J. Cohoon

Auto-generated profile, based on publicly available information

Travis J. Cohoon

Scripps Prebys Cardiovascular Institute, Department of Medicine, La Jolla, United States of America

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 June 2023 in Journal of the Society for Cardiovascular Angiography & Interventions
Verified
Journal Article
Open access
ARAriel Roguin
Ariel Roguin
PWPerry Wu
Perry Wu
TCTravis Cohoon
Travis Cohoon
FGFahad Gul
Fahad Gul
GNGeorge Nasr
George Nasr
MKMorton J. Kern
Morton J. Kern
Radiation exposure in the cardiac catheterization laboratory (CCL) is an occupational hazard that predisposes health care workers to the development of adverse health effects such as cataracts, cancer, and orthopedic injury. To mitigate radiation exposure, personal protective shielding as well as permanently installed shields reduces these adverse effects. Yet, heavy protective lead aprons and poor ergonomics required for positioning movable shields remain barriers to a safer environment. Recent innovations to enhance personal protective equipment and revolutionize fixed shielding systems will permit the CCL team to work in a personal “lead-free” environment, markedly reducing occupational hazards. The purpose of this review is to update the status and future of radiation protection in the CCL.

26 June 2020 in Personalized Medicine
Verified
Journal Article
Closed access
TCTravis J Cohoon
Travis J Cohoon
SBSanjeev P. Bhavnani
Sanjeev P. Bhavnani
The rapid development of digital health devices has enabled patients to engage in their care to an unprecedented degree and holds the possibility of significantly improving the diagnosis, treatment...

3 April 2023
Verified
Other
Open access
ZZZehua Zhu
Zehua Zhu
Amir ArefAmir Aref
Amir Aref
TCTravis J. Cohoon
Travis J. Cohoon
TBThanh U. Barbie
Thanh U. Barbie
YIYu Imamura
Yu Imamura
DBDavid A Barbie
David A Barbie
Although the roles of mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) signaling in KRAS-driven tumorigenesis are well established, KRAS activates additional pathways required for tumor maintenance, the inhibition of which are likely to be necessary for effective KRAS-directed therapy. Here, we show that the IκB kinase (IKK)–related kinases Tank-binding kinase-1 (TBK1) and IKKϵ promote KRAS-driven tumorigenesis by regulating autocrine CCL5 and interleukin (IL)-6 and identify CYT387 as a potent JAK/TBK1/IKKϵ inhibitor. CYT387 treatment ablates RAS-associated cytokine signaling and impairs Kras-driven murine lung cancer growth. Combined CYT387 treatment and MAPK pathway inhibition induces regression of aggressive murine lung adenocarcinomas driven by Kras mutation and p53 loss. These observations reveal that TBK1/IKKϵ promote tumor survival by activating CCL5 and IL-6 and identify concurrent inhibition of TBK1/IKKϵ, Janus-activated kinase (JAK), and MEK signaling as an effective approach to inhibit the actions of oncogenic KRAS.Significance: In addition to activating MAPK and PI3K, oncogenic KRAS engages cytokine signaling to promote tumorigenesis. CYT387, originally described as a selective JAK inhibitor, is also a potent TBK/IKKϵ inhibitor that uniquely disrupts a cytokine circuit involving CCL5, IL-6, and STAT3. The efficacy of CYT387-based treatment in murine Kras-driven lung cancer models uncovers a novel therapeutic approach for these refractory tumors with immediate translational implications. Cancer Discov; 4(4); 452–65. ©2014 AACR.This article is highlighted in the In This Issue feature, p. 377

3 April 2023
Verified
Other
Open access
EAEsra Akbay
Esra Akbay
SKShohei Koyama
Shohei Koyama
JCJulian Carretero
Julian Carretero
AAAbigail Altabef
Abigail Altabef
JTJeremy H. Tchaicha
Jeremy H. Tchaicha
KWKwok-Kin Wong
Kwok-Kin Wong
- PDF file 2020K, Supplementary figures 1-11. For the mouse experiments tumor bearing lungs were classified as mildly sick and severely sick based on the tumor burden as determined by right lung lobe weights. Oncogene induced immunosuppressive environment manifested as compromised T cell function, elevation in the levels of tumor promoting cytokines, and changes in lung hematopoietic population was observed in the mildy sick mice in addition to the severely sick EGFR mutant mice. Anti PD-1 antibody treatment did not show efficacy in the Kras driven tumors despite the expression of the PD-1 ligand

3 April 2023
Verified
Other
Open access
EAEsra Akbay
Esra Akbay
SKShohei Koyama
Shohei Koyama
JCJulian Carretero
Julian Carretero
AAAbigail Altabef
Abigail Altabef
JTJeremy H. Tchaicha
Jeremy H. Tchaicha
KWKwok-Kin Wong
Kwok-Kin Wong

3 April 2023
Verified
Other
Open access
EAEsra Akbay
Esra Akbay
SKShohei Koyama
Shohei Koyama
JCJulian Carretero
Julian Carretero
AAAbigail Altabef
Abigail Altabef
JTJeremy H. Tchaicha
Jeremy H. Tchaicha
KWKwok-Kin Wong
Kwok-Kin Wong